Product
AT-1501
Aliases
Tegoprubart
7 clinical trials
7 indications
Indication
IgA NephropathyIndication
IgA nephropathyIndication
Kidney Transplant RejectionIndication
Kidney TransplantIndication
Type 1 Diabetes MellitusIndication
Amyotrophic lateral sclerosisIndication
Diabetes MellitusClinical trial
A Phase 2a, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of AT-1501 in Patients With IgA NephropathyStatus: Terminated, Estimated PCD: 2023-07-31
Clinical trial
AT-1501-K207: BESTOW: A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney TransplantationStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
AT-1501-K209: BESTOW-EXTENSION: A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant RecipientsStatus: , Estimated PCD: 2029-12-01
Clinical trial
AT-1501-I206: An Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Transplanted Islet Cells and AT-1501 Immunomodulation in Adults With Brittle Type 1 DiabetesStatus: Withdrawn, Estimated PCD: 2024-08-01
Clinical trial
A Phase 1b, Multicenter, Open Label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AT 1501 in Patients Undergoing Kidney TransplantStatus: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Phase 2a Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Multiple Doses of AT-1501 in Adults With ALSStatus: Completed, Estimated PCD: 2022-03-24
Clinical trial
A Pilot Study Assessing the Safety of Using a Monoclonal Antibody Against Cluster of Differentiation 40 (CD40) Ligand to Achieve a Calcineurin Inhibitor-free Immunosuppression Regimen in Patients With Type 1 Diabetes Mellitus (T1D) and Problematic Hypoglycemia Undergoing Islet Cell TransplantationStatus: Recruiting, Estimated PCD: 2029-03-01